Report Library
All ReportsMultiple Myeloma KOL Insight - US
January 10, 2023
This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for multiple myeloma. Drug adverse events and critical unmet needs are also discussed. Key therapies highlighted include the anti-CD38 antibodies Darzalex and Sarclisa, the CAR-T therapies Abecma and Carvykti, and the bispecific antibody Tecvayli.
Please note that this interview was conducted in October 2022.
If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).
Biomedtracker's KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.
For our disclosures, please read the Biomedtracker Research Standards.
Indications Covered: | Multiple Myeloma (MM) |
Additional Resources: